Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) Insider Sells 6,441 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,441 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the sale, the insider now owns 85,819 shares of the company’s stock, valued at $465,997.17. This trade represents a 6.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Linda Llewelyn also recently made the following trade(s):

• On Wednesday, January 15th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The shares were sold at an average price of $5.80, for a total value of $37,363.60.
• On Monday, December 16th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The shares were sold at an average price of $7.88, for a total value of $50,762.96.

Health Catalyst Trading Down 3.0 %

HCAT stock opened at $5.23 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a twelve month low of $5.20 and a twelve month high of $9.24. The company has a market cap of $318.25 million, a P/E ratio of -3.87 and a beta of 1.34. The business has a fifty day moving average of $6.24 and a 200-day moving average of $7.30.

Wall Street Analyst Weigh In

HCAT has been the topic of a number of research analyst reports. Piper Sandler lowered their target price on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, February 11th. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a research report on Wednesday, January 8th. Wells Fargo & Company reduced their price objective on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Stephens increased their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Finally, Citigroup cut their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Health Catalyst presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.20.

Institutional Trading of Health Catalyst

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mackenzie Financial Corp acquired a new position in Health Catalyst during the 4th quarter valued at about $248,000. PharVision Advisers LLC bought a new stake in shares of Health Catalyst during the fourth quarter worth approximately $185,000. Two Sigma Advisers LP lifted its holdings in Health Catalyst by 72.7% in the fourth quarter. Two Sigma Advisers LP now owns 29,700 shares of the company’s stock valued at $210,000 after buying an additional 12,500 shares during the period. Two Sigma Investments LP acquired a new position in shares of Health Catalyst in the 4th quarter valued at $496,000. Finally, ProShare Advisors LLC boosted its holdings in Health Catalyst by 52.7% during the fourth quarter. ProShare Advisors LLC now owns 16,854 shares of the company’s stock worth $119,000 after buying an additional 5,815 shares during the last quarter. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.